Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : EQUIDYNE CORP: IJX (AMEX) -- Ignore unavailable to you. Want to Upgrade?

To: Fraser Parsons who wrote (132)	9/12/2000 5:05:12 PM
From: Skywatcher	Read Replies (1) \| Respond to of 179

WOW for today...finally the buying from whom I suspect is the company for the last few days...and when that was over, the stock popped right up to 4 at the end of the day. I am more enthused about the company and product right now. Hope the market turndown doesn't wreck it, but I suspect that the sales efforts and acceptance of the product is gonna work out just fine. chris

To: Fraser Parsons who wrote (132)	10/3/2000 3:47:27 PM
From: Skywatcher	Read Replies (1) \| Respond to of 179

BIG STEP ONE!!!Equidyne Corporation Announces Agreement With Rite Aid for Exclusive Retail Distribution of INJEX Products Through its Stores Nationwide Equidyne and Rite Aid Team-Up for Distribution of INJEX(TM)at Rite Aid's 3,800 Stores WESTFORD, Mass. & CAMP HILL, Pa.--(BW HealthWire)--Oct. 3, 2000-- EQUIDYNE CORPORATION (OTCBB:INJX - news) announced today an agreement with national pharmacy chain Rite Aid Corporation (NYSE, PSE:RAD) to exclusively market and distribute the INJEX(TM) products through its retail outlets. Rite Aid is one of the nation's largest retail pharmacy chains, serving millions of customers each day through its approximately 3,800 neighborhood locations in 30 states on both the East and West Coasts and the District of Columbia. Under the terms of the agreement Rite Aid is the exclusive national retail distributor of the INJEX(TM) needle-free drug delivery system in the areas served by their stores through April of 2001. Equidyne will continue to appoint independent dealers and pharmacies, and other pharmacy chains in areas of the country not served by Rite Aid stores. J. Randall Nelson, President and Chief Executive Officer, stated, ``Rite Aid enjoys a reputation for quality products and services and is very committed to diabetes care at their pharmacies. We are extremely pleased and fortunate to have them as our national retail distributor for the INJEX(TM) products. Equidyne will provide educational material to all Rite Aid pharmacies and will participate in Rite Aid's `diabetes day' events. Rite Aid will work closely with Equidyne to provide valuable feedback on the product. We firmly believe this new channel of distribution will significantly benefit Equidyne and we look forward to a long and successful relationship with Rite Aid.'' ``Rite Aid is very committed to diabetes awareness and part of that commitment includes the availability of leading edge technology through all of our pharmacies. We are excited to be part of this significant technological advancement that will differentiate Rite Aid from all other chain pharmacies,'' said Greg Drew, Rite Aid Vice President, Pharmacy Health Services. Equidyne Corporation, through Equidyne Systems, Inc., a wholly-owned subsidiary based in San Diego, California, and Rosch AG Medizintechnik, its partially-owned investment based in Berlin, Germany (Additional information at: www.roeschnet.com), is focused on becoming the worldwide leader in needle-free drug delivery systems for subcutaneous and intramuscular injections. Equidyne is responsible for the U.S., Canada, South America and the Asian markets while Rosch AG is responsible for the European market. The INJEX(TM) needle-free injector is a compact, uncomplicated device that delivers a virtually painless injection through the skin in a fraction of a second, and eliminates needle stick and disposal problems. For medications requiring injection, we believe the INJEX(TM) System is by far the most comfortable and economical product on the market. Rite Aid is one of the nation's leading drugstore chains with annual revenues of over $14 billion and approximately 3,800 stores in 30 states and the District of Columbia. Rite Aid also owns approximately 15 percent of drugstore.com, a leading online source for health, beauty and pharmacy products. Information about Rite Aid, including corporate background and press releases, can be found at the company's Web site at www.riteaid.com. Chris

To: Fraser Parsons who wrote (132)	2/6/2001 11:49:54 AM
From: Skywatcher	Respond to of 179

Equidyne Corporation and Rosch AG Announce Worldwide Agreement With Pharmacia Corporation -INJEX(TM)System to be Used With Pharmacia's Recombinant Growth Hormone, GENOTROPIN in 60 Countries- SAN DIEGO--(BW HealthWire)--Jan. 26, 2001-- EQUIDYNE CORPORATION (AMEX:IJX - news) announced today an exclusive world-wide agreement between Equidyne Corporation, Rosch AG Medizintechnik and Pharmacia Corporation to sell the INJEX(TM) Needle-Free Injection System for use with Pharmacia's growth hormone product, GENOTROPIN (somatropin; rDNA origin). GENOTROPIN, first introduced in 1987, is the world's leading brand of growth hormone and is marketed in more than 60 countries around the world. Under the terms of the agreement, Pharmacia Corporation (Stockholm, Sweden) has exclusive rights to use the INJEX(TM) System with its GENOTROPIN until 2006, and the agreement may be extended for additional two-year periods. J. Randall Nelson, Chairman and Chief Executive Officer, stated, ``We are very excited about this worldwide agreement between Equidyne and Rosch AG, and Pharmacia Corporation. Pharmacia is clearly the global leader in the marketing of human growth hormone with its GENOTROPIN. The market for this group of medications, which are administered primarily to children, is nearly $1 billion worldwide. We believe this agreement is the breakthrough that emphasizes the versatility of use, comfort and economy of the INJEX(TM) System and is the precursor to more pharmaceutical partnerships.'' Equidyne Corporation (www.equidyne.com), through Equidyne Systems, Inc., a wholly owned subsidiary based in San Diego, California, is focused on becoming the worldwide leader in needle-free drug delivery systems for subcutaneous and intramuscular injections. The INJEX(TM) needle-free injector is a compact, uncomplicated device that delivers a virtually painless injection through the skin in a fraction of a second, and eliminates needle stick and disposal problems. For medications requiring injection, we believe the INJEX(TM) System is by far the most comfortable and economical product on the market. PHARMACIAAAAAA....now we're talking! chris

To: Fraser Parsons who wrote (132)	2/6/2001 11:50:16 AM
From: Skywatcher	Respond to of 179

< SAN DIEGO, Calif. (Dow Jones)--Equidyne Corp. (IJX) received reimbursement approval for its Injex system from four of the top six Pharmacy Benefit Managers. Pharmacy Benefit Managers manage the pharmacy benefits for insurance companies, managed care groups and employer groups. In a press release Tuesday, Equidyne said the four pharmacy benefit managers cover more than 70 million people. The Injex system is a needle-free drug delivery system. -Stephen Lee; Dow Jones Newswires; 201-938-5400 (END) DOW JONES NEWS 02-06-01 11:48 AM